halofuginone has been researched along with Chronic Illness in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cypel, M; Guan, Z; Hirayama, S; Hwang, DM; Juvet, SC; Keller, TL; Keshavjee, S; Liu, M; Martinu, T; Matsuda, Y; Oishi, H; Saito, T; Sato, M; Whitman, MR | 1 |
Chen, W; Cheng, H; Li, Z; Pan, B; Song, G; Tian, J; Xu, K; Zeng, L | 1 |
2 other study(ies) available for halofuginone and Chronic Illness
Article | Year |
---|---|
Halofuginone treatment reduces interleukin-17A and ameliorates features of chronic lung allograft dysfunction in a mouse orthotopic lung transplant model.
Topics: Animals; Chronic Disease; Disease Models, Animal; Graft Rejection; Interleukin-17; Lung Transplantation; Male; Mice; Mice, Inbred C57BL; Piperidines; Protein Synthesis Inhibitors; Quinazolinones; Th17 Cells; Transplantation, Homologous | 2016 |
Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Transplantation; Cell Differentiation; Chronic Disease; Cytokines; Female; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Piperidines; Quinazolinones; Skin Diseases; Th17 Cells; Time Factors; Transplantation, Homologous | 2012 |